RU2526517C2 - Антитела против g-белка распираторно-синцитиального вируса (rsv) - Google Patents

Антитела против g-белка распираторно-синцитиального вируса (rsv) Download PDF

Info

Publication number
RU2526517C2
RU2526517C2 RU2010120879/10A RU2010120879A RU2526517C2 RU 2526517 C2 RU2526517 C2 RU 2526517C2 RU 2010120879/10 A RU2010120879/10 A RU 2010120879/10A RU 2010120879 A RU2010120879 A RU 2010120879A RU 2526517 C2 RU2526517 C2 RU 2526517C2
Authority
RU
Russia
Prior art keywords
seq
positions
rsv
region consisting
antibodies
Prior art date
Application number
RU2010120879/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2010120879A (ru
Inventor
Лоренс М. КАУВАР
Эллен Дж. КОЛЛАРИНИ
Брюс КИТ
Орит ФУРД
Original Assignee
Треллис Байосайенс,Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Треллис Байосайенс,Инк. filed Critical Треллис Байосайенс,Инк.
Publication of RU2010120879A publication Critical patent/RU2010120879A/ru
Application granted granted Critical
Publication of RU2526517C2 publication Critical patent/RU2526517C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
RU2010120879/10A 2007-10-25 2008-10-24 Антитела против g-белка распираторно-синцитиального вируса (rsv) RU2526517C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46907P 2007-10-25 2007-10-25
US61/000,469 2007-10-25
US8940108P 2008-08-15 2008-08-15
US61/089,401 2008-08-15
PCT/US2008/081175 WO2009055711A2 (en) 2007-10-25 2008-10-24 Anti-rsv g protein antibodies

Publications (2)

Publication Number Publication Date
RU2010120879A RU2010120879A (ru) 2011-11-27
RU2526517C2 true RU2526517C2 (ru) 2014-08-20

Family

ID=40580419

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010120879/10A RU2526517C2 (ru) 2007-10-25 2008-10-24 Антитела против g-белка распираторно-синцитиального вируса (rsv)

Country Status (14)

Country Link
US (3) US7736648B2 (https=)
EP (1) EP2214711B1 (https=)
JP (2) JP5808536B2 (https=)
KR (1) KR101671452B1 (https=)
CN (1) CN101808663B (https=)
AU (1) AU2008316703B2 (https=)
BR (1) BRPI0819210A2 (https=)
CA (1) CA2703667C (https=)
IL (1) IL205257A (https=)
MX (1) MX2010004482A (https=)
NZ (1) NZ585589A (https=)
RU (1) RU2526517C2 (https=)
WO (1) WO2009055711A2 (https=)
ZA (1) ZA201003131B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10590196B2 (en) 2014-12-05 2020-03-17 Memorial Sloan-Kettering Cancer Center Antibodies targeting G-protein coupled receptor and methods of use
US10633426B2 (en) 2014-12-05 2020-04-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof
US11732049B2 (en) 2017-01-27 2023-08-22 Ngm Biopharmaceuticals, Inc. Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor
US11845802B2 (en) 2018-07-27 2023-12-19 Ngm Biopharmaceuticals, Inc. Combination therapy with a glucagon receptor (GCGR) antibody and an anti-CD3 antibody

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874547B2 (ja) * 2002-11-26 2012-02-15 ギリアード サイエンシーズ， インコーポレイテッド 勾配によるリポソームへの薬物充填方法
BRPI0819210A2 (pt) * 2007-10-25 2015-06-23 Trellis Bioscience Inc Anticorpos de proteína g anti-rsv
US9718876B2 (en) 2011-11-17 2017-08-01 Aimm Therapeutics B.V. RSV G protein specific antibodies
ES2668104T3 (es) * 2011-12-28 2018-05-16 Immunoqure Ag Procedimiento de aislamiento de anticuerpos humanos
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2014170257A1 (en) * 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g protein
CN111303278B (zh) * 2013-04-15 2022-09-06 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
EA035846B1 (ru) * 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
JP2017512208A (ja) * 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
CN103911389A (zh) * 2014-04-09 2014-07-09 南昌大学 一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
CN105542003B (zh) * 2016-03-01 2019-12-06 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
CA3079604A1 (en) * 2017-10-13 2019-04-18 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus g protein central conserved region
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
EP3833677A4 (en) * 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED RSV PASSIVE AND ACTIVE VACCINES
AU2020227545B2 (en) 2019-02-28 2023-10-19 Km Biologics Co., Ltd. RSV F/G chimeric vaccine
WO2021046390A1 (en) 2019-09-06 2021-03-11 Silgan White Cap LLC Tethered, hinged closure
EP4031171A1 (en) * 2019-09-20 2022-07-27 Universiteit Antwerpen A novel human respiratory syncytial virus strain and its use
KR20220122656A (ko) 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
EP4429966A4 (en) 2021-11-08 2026-01-14 Silgan White Cap LLC PROJECTION ON THE NECK OF A CONTAINER
WO2024027708A1 (zh) * 2022-08-02 2024-02-08 诺纳生物（苏州）有限公司 Msln抗体药物偶联物
WO2025106427A1 (en) * 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025194126A1 (en) * 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2160119C2 (ru) * 1993-05-25 2000-12-10 Американ Цианамид Компани Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (варианты)
WO2002032942A2 (en) * 2000-10-18 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for modulating rsv infection and immunity
EP1477494A1 (en) * 1996-07-12 2004-11-17 Aventis Pasteur Limited Subunit respiratory syncytial virus vaccine preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
EP1638603A1 (en) 1999-01-22 2006-03-29 The Government of the United States represented by the Secretary of the Department of Health and Human Services Methods for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance p by using anti-substance p antibodies
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN1986569A (zh) * 2005-12-23 2007-06-27 首都儿科研究所 人源抗呼吸道合胞病毒中和性基因工程Fab抗体
WO2007094423A1 (ja) * 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2009528828A (ja) 2006-03-06 2009-08-13 シムフォゲン・アクティーゼルスカブ 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体
WO2008008858A2 (en) 2006-07-12 2008-01-17 Trellis Bioscience, Inc. Cellspot™ applications
BRPI0819210A2 (pt) * 2007-10-25 2015-06-23 Trellis Bioscience Inc Anticorpos de proteína g anti-rsv

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2160119C2 (ru) * 1993-05-25 2000-12-10 Американ Цианамид Компани Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (варианты)
EP1477494A1 (en) * 1996-07-12 2004-11-17 Aventis Pasteur Limited Subunit respiratory syncytial virus vaccine preparation
WO2002032942A2 (en) * 2000-10-18 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for modulating rsv infection and immunity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDERSON L J ET AL: "IDENTIFICATION OF EPITOPES ON RESPIRATORY SYNCYTIAL VIRUS PROTEINS BY COMPETITIVE BINDING IMMUNOASSAY", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 23, no. 3, 1986, pages 475-480. WALSH ET AL.: 'Monodonal antibody neutralization escape mutants of respiratory syncytial virus. with unique alterations in the attachment (G) protein.' J GEN VIROL. vol. 79, no. PT 3, 1998, pages 479 - 87. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10590196B2 (en) 2014-12-05 2020-03-17 Memorial Sloan-Kettering Cancer Center Antibodies targeting G-protein coupled receptor and methods of use
US10633426B2 (en) 2014-12-05 2020-04-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof
US10906956B2 (en) 2014-12-05 2021-02-02 Memorial Sloan Kettering Cancer Center Methods of treatments using chimeric antigen receptors targeting G-protein coupled receptor
RU2762359C2 (ru) * 2014-12-05 2021-12-20 Мемориал Слоан-Кеттеринг Кэнсер Сентер Химерные антигенные рецепторы, нацеленные на рецептор, связанный с g-белками, и их применение
US11566071B2 (en) 2014-12-05 2023-01-31 Memorial Sloan Kettering Cancer Center Nucleic acid molecules encoding anti-GPRC5D antibodies
US11820806B2 (en) 2014-12-05 2023-11-21 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof
US11866478B2 (en) 2014-12-05 2024-01-09 Memorial Sloan-Kettering Cancer Center Nucleic acid molecules encoding chimeric antigen receptors targeting G-protein coupled receptor
US11732049B2 (en) 2017-01-27 2023-08-22 Ngm Biopharmaceuticals, Inc. Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor
US11845802B2 (en) 2018-07-27 2023-12-19 Ngm Biopharmaceuticals, Inc. Combination therapy with a glucagon receptor (GCGR) antibody and an anti-CD3 antibody

Also Published As

Publication number Publication date
US20100285022A1 (en) 2010-11-11
AU2008316703A2 (en) 2010-07-22
JP2011500091A (ja) 2011-01-06
US9321830B2 (en) 2016-04-26
CA2703667C (en) 2015-12-29
CN101808663B (zh) 2015-09-30
KR101671452B1 (ko) 2016-11-17
RU2010120879A (ru) 2011-11-27
US20130034564A1 (en) 2013-02-07
AU2008316703B2 (en) 2012-09-27
EP2214711A4 (en) 2011-12-21
WO2009055711A2 (en) 2009-04-30
ZA201003131B (en) 2011-03-30
CA2703667A1 (en) 2009-04-30
US20090130120A1 (en) 2009-05-21
US8273354B2 (en) 2012-09-25
NZ585589A (en) 2012-07-27
IL205257A0 (en) 2010-12-30
JP5808536B2 (ja) 2015-11-10
AU2008316703A1 (en) 2009-04-30
IL205257A (en) 2014-12-31
EP2214711A2 (en) 2010-08-11
KR20100091195A (ko) 2010-08-18
CN101808663A (zh) 2010-08-18
EP2214711B1 (en) 2018-08-15
US7736648B2 (en) 2010-06-15
BRPI0819210A2 (pt) 2015-06-23
JP2015078231A (ja) 2015-04-23
WO2009055711A3 (en) 2009-09-24
MX2010004482A (es) 2010-07-06

Similar Documents

Publication Publication Date Title
RU2526517C2 (ru) Антитела против g-белка распираторно-синцитиального вируса (rsv)
CN113943368B (zh) 一种新型冠状病毒及其突变体的单克隆抗体及其应用
CN113929774B (zh) 一种新型冠状病毒及其突变体的单克隆抗体及其应用
US20110189171A1 (en) Recombinant antibodies for treatment of respiratory syncytial virus infections
US20240101646A1 (en) Sars-cov-2 coronavirus antibodies and uses thereof
RS50157B (sr) Neutrališuća visoko afinitivna humana monoklonalna antitela specifična za rsv f-protein i postupci za njihovu proizvodnju
US10030069B2 (en) High affinity human antibodies to human cytomegalovirus (CMV) gB protein
CN114174331B (zh) 结合人类偏肺病毒融合蛋白的抗体及其用途
CN116041494A (zh) 一种针对SARS-CoV或SARS-CoV-2的单克隆抗体、其制备方法及应用
CN116178530A (zh) 抗体在治疗SARS-CoV-2感染的用途
WO2021228135A1 (zh) 制备抗原结合单元的方法
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
WO2024173657A9 (en) Antibodies to human pneumoviruses and methods of use therefor
WO2025140539A1 (en) Ultrapotent broardly neutralizing antibodies against sars-cov-2 variants and methods of use thereof
US20240239874A2 (en) Fully Human Monoclonal Antibodies that Broadly Neutralize SARS-COV-2
RU2779105C2 (ru) Антитела к респираторно-синцитиальному вирусу и способы их получения и применения
CN121426940A (zh) 特异性结合呼吸道合胞病毒的抗体及其应用
CN121800913A (zh) 一种乙型脑炎病毒和寨卡病毒的单抗及其应用
HK40064555B (zh) 制备抗原结合单元的方法

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171025